Advanced Search
Contact | Corporate | Help

High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia

Sponsors:
  • Eye Center of Northern Colorado, P.C.
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
HD-LIPT
  • Retinal Diseases
  • Telangiectasis
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: ranibizumab 2.0mg
Enrollment:
6

Additional information about NCT01205035.


SourceSolution © 2008-2012